Metrics to compare | VETO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVETOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.4x | 14.2x | −0.4x | |
PEG Ratio | −18.06 | 0.32 | 0.00 | |
Price/Book | 1.4x | 2.3x | 2.6x | |
Price / LTM Sales | 1.6x | 3.3x | 3.0x | |
Upside (Analyst Target) | 20.6% | 15.1% | 54.6% | |
Fair Value Upside | Unlock | 11.3% | 9.7% | Unlock |
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a subsidiary of Soparfin SCA.